Falsolieva 250mg Injection (Fulvestrant): Targeted Endocrine Therapy for Advanced Breast Cancer Falsolieva 250 mg Injection is a specialized hormonal therapy containing the active ingredient Fulvestrant. It belongs to a class of medications known as selective estrogen receptor degraders (SERDs). Unlike traditional hormone therapies that merely block estrogen, Falsolieva works by significantly reducing the number of estrogen receptors in the body, providing a powerful intervention for hormone-receptor-positive (HR+) malignancies. Manufactured to meet global quality standards, Falsolieva is a critical tool for oncologists managing postmenopausal breast cancer. Therapeutic Indications: Clinical Scope HR-Positive Metastatic Breast Cancer: For postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer not previously treated with endocrine therapy. Progressive Advanced Breast Cancer: For women whose disease has progressed following anti-estrogen therapy (such as tamoxifen or aromatase inhibitors). Combination Therapy: Often used in combination with targeted therapies like CDK4/6 inhibitors (e.g., Palbociclib, Abemaciclib) to enhance clinical outcomes in metastatic settings. Mechanism of Action: How Falsolieva Works Competitive Binding: Fulvestrant binds to estrogen receptors (ER) with an affinity significantly higher than that of tamoxifen. Receptor Degradation: Once bound, it causes the estrogen receptor to change shape, leading to the degradation and eventual destruction of the receptor protein. Transcriptional Blockade: By reducing the number of available receptors, it prevents estrogen from “locking“ into the cancer cell, effectively stopping the signals that trigger tumor growth. No Agonist Effects: Unlike some other therapies, Falsolieva has no estrogen-mimicking effects, making it a pure antagonist. Professional Administration and Dosage Route of Administration: Falsolieva is administered as a slow intramuscular (IM) injection into the buttocks (gluteal area). Standard Dosing Regimen: The recommended dose is 500mg (administered as two 250mg injections, one in each buttock). Schedule: Typically administered on days 1, 15, and 29 of the first month, followed by once-monthly maintenance doses. Clinical Setting: Due to the specialized nature of the injection, it must be administered by a healthcare professional. Safety Profile and Patient Monitoring Injection Site Reactions: Temporary pain, inflammation, or bruising at the site of the IM injection. Hormonal Symptoms: Hot flashes, bone pain, and nausea are common but usually manageable. Hepatic Function: Liver function tests (LFTs) are recommended for patients with known hepatic impairment, as the drug is metabolized in the liver. Thromboembolic Events: While rare, monitoring for signs of blood clots is standard clinical practice for hormonal therapies. Why Choose Ernest Oncology? 100% Genuine Supply: We source Falsolieva directly from GMP-certified channels, ensuring every batch is authentic with an optimal shelf life. Global Distribution Reach: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Temperature-Controlled Logistics: Our team is expert in handling sensitive oncology products, ensuring they reach their destination under the required storage conditions. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals and pharmacy networks worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 260 MG Injection (Paclitaxel): High-Dose Chemotherapeutic Solution for Advanced Oncology PACLIEVA 260 MG Injection is a maximum-strength antineoplastic formulation containing Paclitaxel, a potent taxane-derived cytotoxic agent. This high-concentration injection is specifically engineered for the intensive treatment of advanced, metastatic, or refractory solid tumors. Manufactured by Zuventus Healthcare, PACLIEVA 260 MG is a cornerstone in international oncology protocols, providing clinicians with the necessary strength for high-dose systemic chemotherapy. Therapeutic Indications and Global Clinical Usage Advanced Ovarian Cancer: Used as primary therapy for advanced carcinoma and for patients who have failed prior platinum-based treatments. Metastatic Breast Cancer: Indicated for patients whose disease has progressed despite standard anthracycline therapy or where combination chemotherapy is required. Non-Small Cell Lung Cancer (NSCLC): Utilized as a first-line treatment in combination with other agents for patients who are not candidates for curative surgery or radiation. AIDS-Related Kaposi’s Sarcoma: Employed as a specialized second-line intervention for advanced cases. The Science of PACLIEVA: Mechanism of Action Protein Binding: Paclitaxel binds specifically to the beta-tubulin subunit of the cell's microtubules. Structural Stabilization: It promotes the assembly of microtubules while simultaneously preventing their disassembly (depolymerization). Mitotic Arrest: By “freezing“ the mitotic spindle, PACLIEVA prevents the cancer cell from completing its division cycle (mitosis). Cellular Apoptosis: The resulting cell-cycle arrest triggers programmed cell death, effectively reducing tumor size and slowing the spread (metastasis) of the disease. Administration and Dosage Protocols Route: Administered exclusively via Intravenous (IV) Infusion by qualified oncology professionals. Preparation: Due to its high concentration, PACLIEVA 260 MG must be properly diluted in 0.9% Sodium Chloride or 5% Dextrose as per strict clinical guidelines. Pre-medication Protocol: To mitigate the risk of severe hypersensitivity, patients must be pre-medicated with corticosteroids, antihistamines, and H2 antagonists (e.g., Dexamethasone, Diphenhydramine, and Ranitidine). Cycle Management: The 260mg strength allows for efficient dosing in regimens typically scheduled every 3 weeks, tailored to the patient’s body surface area (BSA). Safety Profile and Clinical Monitoring Hematological Monitoring: Regular blood work is essential to track bone marrow suppression, specifically neutropenia, which is a dose-limiting factor. Neurotoxicity Vigilance: Clinicians monitor for peripheral neuropathy, often manifesting as tingling or numbness in the extremities. Infusion Reaction Monitoring: Close observation is required during the first hour of infusion for symptoms like flushing, skin reactions, or dyspnea. Hepatic Monitoring: Liver function tests (LFTs) are periodically conducted to ensure the patient can effectively metabolize the drug. Storage and Handling Instructions Storage: Keep in the original carton at room temperature (20°C to 25°C) to protect the vial from light. Cytotoxic Handling: As a hazardous antineoplastic agent, PACLIEVA should be handled using specialized safety equipment (PPE) and disposed of according to international biohazard protocols. Why Partner with Ernest Oncology for Global Exports? 100% Genuine Supply: We source products directly from GMP-certified manufacturers, guaranteeing authentic medication with optimal shelf life. Global Distribution Network: We facilitate rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Regulatory Expertise: Our team manages all export documentation, including Certificates of Analysis (CoA) and necessary permits, ensuring smooth customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale pricing to support hospitals, oncology centers, and pharmaceutical importers. Secure Logistics: We utilize industry-standard packaging to maintain product stability and integrity during long-distance international transit 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 100 MG Injection (Paclitaxel): Advanced Chemotherapeutic Solution for Targeted Oncology PACLIEVA 100 MG Injection is a high-concentration antineoplastic medication containing Paclitaxel, a potent agent belonging to the taxane family of drugs. As a cornerstone of modern chemotherapy, PACLIEVA 100 MG is widely utilized in international clinical settings to combat various forms of advanced and metastatic solid tumors. Therapeutic Indications and Clinical Applications Advanced Ovarian Cancer: Used as first-line therapy (often in combination with platinum agents) and as second-line therapy for patients who have not responded to standard treatments. Metastatic Breast Cancer: Highly effective for patients where anthracycline treatment has failed or is not indicated. Non-Small Cell Lung Cancer (NSCLC): Prescribed for advanced cases in patients who are not eligible for curative surgery or radiation therapy. AIDS-Related Kaposi’s Sarcoma: Utilized as a specialized second-line treatment for patients with advanced disease. The Science of PACLIEVA: Mechanism of Action Binding to Tubulin: Paclitaxel binds specifically to the beta-tubulin subunit of the cell's microtubules. Prevention of Depolymerization: It stabilizes the microtubules and prevents them from breaking down. Mitotic Arrest: Because the microtubules cannot reorganize, the cancer cell is “locked“ in the middle of division (mitosis). Programmed Cell Death: This arrest triggers apoptosis (cell death), preventing the tumor from growing or spreading (metastasizing) further. Administration and Dosage Protocols Route: Administered solely via Intravenous (IV) Infusion by trained oncology professionals. Infusion Schedule: Typically administered over a 3-hour or 24-hour period, depending on the specific protocol (e.g., every 3 weeks or a weekly dose-dense regimen). Pre-medication Requirement: To mitigate the risk of severe hypersensitivity reactions, patients are usually pre-medicated with corticosteroids (like dexamethasone), antihistamines, and H2 antagonists. Specialized Equipment: PACLIEVA must be administered using non-PVC infusion sets and an in-line filter to ensure drug stability and patient safety. Safety Profile and Professional Monitoring Myelosuppression: Regular blood work is mandatory to monitor for neutropenia (low white blood cell count), which is the dose-limiting toxicity. Peripheral Neuropathy: Monitoring for numbness, tingling, or pain in the extremities is essential for long-term care. Infusion Reactions: Close observation during the first hour of infusion for symptoms such as dyspnea, hypotension, or angioedema. Cardiac Monitoring: While infrequent, vital signs should be monitored for bradycardia or other rhythmic disturbances. Storage and Handling Guidelines Storage: Store in the original carton at controlled room temperature (20°C to 25°C) to protect from light. Handling: As a cytotoxic drug, PACLIEVA should be handled with caution by healthcare workers using proper personal protective equipment (PPE) and following hazardous waste disposal protocols. Why Choose Ernest Oncology? Verified Authenticity: We source products directly from GMP-certified manufacturers, guaranteeing 100% genuine medication with optimal shelf life. Global Logistics Network: We specialize in rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Professional Regulatory Support: Our team handles all export documentation, Certificates of Analysis (CoA), and customs requirements for a seamless transaction. Bulk Supply Efficiency: As a bulk supplier and distributor, we provide competitive wholesale pricing for hospitals, oncology centers, and government health departments. Secure Packaging: We utilize specialized pharmaceutical-grade packaging to maintain product integrity during long-distance transit. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Pertuzumab Injection: Advanced HER2-Dimerization Inhibitor for Targeted Oncology – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Pertuzumab Injection remains a cornerstone in the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies. As a recombinant humanized monoclonal antibody, Pertuzumab represents a sophisticated class of targeted therapy—HER2-dimerization inhibitors (HDIs)—designed to disrupt the signaling pathways that drive aggressive tumor proliferation. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Pertuzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for global medical procurement. Technical Product Profile: Pertuzumab Injection Pertuzumab is a biological agent that targets the extracellular domain of the HER2 protein, specifically preventing it from pairing with other members of the HER family. Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: The Science of Dimerization Blockade Pertuzumab’s therapeutic efficacy lies in its ability to target the HER2 dimerization domain (Domain II). Prevention of Heterodimerization: Pertuzumab inhibits the ligand-induced pairing of HER2 with other HER receptors, most notably HER3. This pairing is the most potent signaling driver for cancer cell survival. Dual Blockade Synergy: When used with Trastuzumab, which binds to Domain IV, the two antibodies provide a comprehensive “Dual Blockade,“ shutting down both ligand-dependent and ligand-independent growth signals. Antibody-Dependent Cellular Cytotoxicity (ADCC): Pertuzumab marks the cancer cells for destruction by the body’s innate immune system, specifically natural killer (NK) cells. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biologicals from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA biological import protocols and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perzumab Injection (Pertuzumab): Targeted HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Perzumab Injection (containing the active ingredient Pertuzumab) represents a critical breakthrough in the treatment of HER2-positive malignancies. As a humanized monoclonal antibody, Perzumab acts as a HER2-dimerization inhibitor, specifically designed to prevent the pairing of HER2 with other HER receptors, thereby shutting down the aggressive growth signals that drive cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Perzumab (Pertuzumab) Perzumab is a biological therapy that targets a different epitope on the HER2 receptor than Trastuzumab, making it an essential component of “dual-blockade“ therapy. Product Specifications Active Ingredient: Pertuzumab Common Strength: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: Monoclonal Antibody (HER2-Dimerization Inhibitor) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: Used as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dimerization Blockade Perzumab specifically targets the extracellular dimerization domain (Domain II) of the Human Epidermal Growth Factor Receptor 2 (HER2). Inhibition of Pairing: It prevents HER2 from forming pairs (dimers) with other HER family members (HER1, HER3, and HER4), most notably the HER2-HER3 heterodimer. Signaling Interruption: By blocking dimerization, it inhibits the downstream signaling pathways that lead to cell proliferation and survival. Immune System Recruitment: It induces Antibody-Dependent Cellular Cytotoxicity (ADCC), recruiting the body's immune cells to destroy the tumor. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical distribution, ensuring that oncology providers have consistent access to high-quality, life-saving biologics. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA import guidelines and technical documentation requirements. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perjeta Injection (Pertuzumab): Advanced HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Perjeta Injection (active ingredient Pertuzumab) represents a breakthrough in targeted biological therapy. As a recombinant humanized monoclonal antibody, Perjeta is the first in a class of agents called HER2-dimerization inhibitors (HDIs), specifically designed to work in synergy with Trastuzumab to provide a more comprehensive blockade of HER2 signaling pathways. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perjeta to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain integrity and rapid logistical execution. Technical Product Profile: Perjeta (Pertuzumab) Perjeta targets a different epitope on the HER2 receptor than Trastuzumab, effectively preventing HER2 from pairing (dimerizing) with other HER receptors (HER1, HER3, and HER4). Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake. Primary Clinical Indications Metastatic Breast Cancer (MBC): In combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dual HER2 Blockade Perjeta’s unique mechanism involves binding to Domain II of the HER2 extracellular domain. Inhibition of Dimerization: Perjeta specifically inhibits the ligand-dependent HER2-HER3 heterodimerization, which is the most potent signaling pair in the HER family. Complementary Action: While Trastuzumab binds to Domain IV to inhibit ligand-independent signaling, Perjeta blocks Domain II. Together, they provide a “dual blockade“ that more effectively shuts down cancer cell growth signals. ADCC Activation: Like other monoclonal antibodies, Perjeta induces Antibody-Dependent Cellular Cytotoxicity (ADCC) to recruit the immune system to destroy tumor cells. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-value biological medications. United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced breast cancer care. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with validated, temperature-monitored shipping to Abu Dhabi and Dubai. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Eposin Injection (Etoposide): Targeted Topoisomerase II Inhibitor for Advanced Oncology – Global Supply by Ernest Oncology In the evolving clinical landscape of 2026, Eposin Injection (containing the active ingredient Etoposide) remains an indispensable antineoplastic agent. As a semi-synthetic derivative of podophyllotoxin, Eposin is a cornerstone in multi-agent chemotherapy regimens designed to treat various solid tumors and hematological malignancies with high precision. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Eposin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous quality standards and validated cold-chain logistics. Technical Product Information: Eposin Injection Eposin is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is supplied as a sterile, non-aqueous solution for intravenous administration after proper dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Common Strengths: 100 mg / 5 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C). Do not freeze. Protect from light. Primary Clinical Indications Small Cell Lung Cancer (SCLC): Typically utilized as a first-line therapy in combination with other chemotherapeutic agents like Cisplatin. Refractory Testicular Tumors: For patients who have already received appropriate surgical and chemotherapeutic treatment. Acute Monocytic and Myelomonocytic Leukemia: Integrated into induction and consolidation protocols. Hodgkin’s & Non-Hodgkin’s Lymphoma: A key component in salvage and high-dose therapy regimens. Choriocarcinoma: Part of multi-drug protocols for gestational trophoblastic tumors. Mechanism of Action: How Eposin Works Eposin exerts its therapeutic effect by inhibiting the enzyme DNA Topoisomerase II, which is essential for DNA replication and transcription. Complex Stabilization: Eposin binds to the DNA-Topoisomerase II complex, preventing the re-ligation of DNA strands. Double-Strand Breaks: This leads to an accumulation of permanent double-strand breaks in the cancer cell's DNA. Mitotic Arrest: The genomic damage triggers the cell's internal checkpoints, arresting the cell cycle in the G2 phase. Apoptosis: The irreparable damage ultimately results in programmed cell death (apoptosis) of the malignant cells. Global Supply Chain: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in the logistical complexities of exporting high-quality oncology injectables from India to key international healthcare markets. United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import standards and safety protocols. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports at competitive rates. Abu Dhabi & UAE: Supporting the UAE’s advanced medical infrastructure with fast-track, secure shipping to major oncology hubs. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA frameworks. South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from WHO-GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Toposar Injection (Etoposide): Precision Topoisomerase II Inhibitor – Global Supply by Ernest Oncology In the advanced oncology landscape of 2026, Toposar Injection (containing the active ingredient Etoposide) remains a critical antineoplastic agent. As a semi-synthetic derivative of podophyllotoxin, Toposar is globally recognized for its efficacy in treating refractory cancers, particularly within the lungs and reproductive system. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Toposar to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous quality control and validated medical-grade logistics. Technical Product Information: Toposar Injection Toposar is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is supplied as a sterile, non-aqueous solution for intravenous administration after proper dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Concentration: 100 mg / 5 mL and 500 mg / 25 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C). Do not freeze. Protect from light during storage. Primary Clinical Indications Small Cell Lung Cancer (SCLC): Often used as a first-line therapy in combination with Cisplatin or Carboplatin. Refractory Testicular Tumors: For patients who have already undergone surgery and chemotherapy with other agents. Non-Hodgkin’s Lymphoma: Integrated into salvage therapy regimens for aggressive lymphomas. Acute Myeloid Leukemia (AML): Utilized in specific induction and consolidation protocols. Pediatric Oncology: Frequently included in protocols for Wilms’ tumor and neuroblastoma. Mechanism of Action: How Toposar Disrupts Cancer Growth Toposar exerts its therapeutic effect by inhibiting the enzyme DNA Topoisomerase II. DNA Cleavage Stabilization: Toposar binds to the Topoisomerase II-DNA complex, preventing the re-ligation of DNA strands. Double-Strand Breaks: This causes an accumulation of permanent breaks in the DNA structure of the cancer cell. Metabolic Failure: The cell is unable to replicate its genetic material or repair the damage, leading to an arrest in the G2 phase. Apoptosis: The irreparable genomic damage triggers programmed cell death (apoptosis) in rapidly dividing malignant cells. Global Supply Chain: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical distribution, ensuring that oncology providers have consistent access to high-quality medications. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all UK pharmaceutical import and safety standards. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports at competitive price points. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure shipping to the Middle East. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA frameworks. South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from WHO-GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Etopos Injection (Etoposide): Advanced Topoisomerase II Inhibitor for Oncology – Global Supply by Ernest Oncology In the precision-driven clinical landscape of 2026, Etopos Injection (containing the active ingredient Etoposide) remains a cornerstone in the treatment of various hematological and solid malignancies. As a semi-synthetic derivative of podophyllotoxin, Etopos is essential for multi-agent chemotherapy protocols designed to achieve high remission rates in lung cancer, testicular cancer, and lymphomas. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide GMP-compliant international distribution of Etopos Injection to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring validated cold-chain integrity and rapid logistical execution. Technical Product Information: Etopos Injection Etopos is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is typically supplied as a sterile non-aqueous solution for slow intravenous infusion after dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Common Strengths: 100 mg / 5 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C); protect from light. (Note: Diluted solutions may have specific stability windows). Primary Clinical Indications Small Cell Lung Cancer (SCLC): Used as first-line therapy in combination with other chemotherapeutic agents. Refractory Testicular Tumors: For patients who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. Acute Monocytic and Myelomonocytic Leukemia: Part of induction and consolidation regimens. Hodgkin’s and Non-Hodgkin’s Lymphoma: Integrated into salvage and high-dose therapy protocols. Ewing's Sarcoma: Utilized in pediatric and adult sarcoma treatments. Mechanism of Action: DNA Topoisomerase II Inhibition Etoposide exerts its cytotoxic effect by stabilizing the “cleavable complex“ between DNA and the enzyme Topoisomerase II. Enzyme Poisoning: Etopos prevents the re-ligation of DNA strands after the enzyme has created a break for untangling. Double-Strand Breaks: This leads to an accumulation of double-strand DNA breaks within the malignant cell. Cell Cycle Arrest: The DNA damage triggers the cell's internal checkpoints, leading to an arrest in the G2 phase. Apoptosis: Irreparable DNA damage ultimately results in programmed cell death (apoptosis). Global Supply & Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring healthcare providers have consistent access to high-quality oncology medications. United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import guidelines and technical documentation requirements. United States: Bulk supply for hospital systems, clinical research organizations, and specialty pharmacies seeking verified Indian pharmaceutical exports. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure shipping to major healthcare hubs. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA standards. South Africa: Strengthening the Southern African oncology sector with cost-effective, high-quality cancer drugs from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383